icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2015
50th Annual Meeting of the European
Association for the Study of the Liver
Vienna, Austria  April 22-26
Back grey_arrow_rt.gif
 
 
 
C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS
 
 
  Reported by Jules Levin
 
EASL 2015 April 22-26 Vienna Austria
 
Fred Poordad* 1, Eric Lawitz1, Julio A. Gutierrez1, Barbara Evans2, Anita Howe2, Hwa-Ping Feng2, Jerry Jing Li2, Peggy Hwang2, Michael Robertson2, Janice Wahl2, Eliav Barr2, Barbara Haber2
 
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, 2Merck & Co., Inc., Whitehouse Station, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif